Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity.
Journal
International journal of endocrinology
ISSN: 1687-8337
Titre abrégé: Int J Endocrinol
Pays: Egypt
ID NLM: 101516376
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
10
2021
accepted:
29
03
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
GnRH agonists (GnRHa) are a useful tool for pretreatment before artificial endometrial preparation for frozen-thawed embryo-transfer (FET). Their prolonged administration has been associated with thyroid dysfunction, both hyper and hypothyroidism. The aim of this study is to investigate the impact of GnRHa administration on thyroid function in women undergoing artificial endometrial preparation. Seventy-eight euthyroid women undergoing endometrial preparation with hormone replacement for FET were retrospectively reviewed. They were divided into two groups according to pretreatment with GnRHa (group A, 42 women) or with an oral contraceptive (group B, 36 women). Group A was subsequently divided into two subgroups according to thyroid autoimmunity presence. Thyroid function has been evaluated and compared among groups and subgroups. Our results did not show any statistically significant differences in age, body mass index, and basal thyroid stimulating hormone (TSH). Total estradiol dosage, duration of treatment, and endometrial thickness were comparable among groups. When TSH was measured 14 days after embryo transfer, no significant differences between the two groups were reported. Among women of group A, TSH was significantly higher only in women with thyroid autoimmunity. GnRHa seems to be associated with thyroid dysfunction in women with thyroid autoimmunity undergoing hormone replacement therapy for FET.
Identifiants
pubmed: 35465072
doi: 10.1155/2022/6331657
pmc: PMC9019438
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6331657Informations de copyright
Copyright © 2022 Loris Marin et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Reprod Sci. 2016 Apr;23(4):515-23
pubmed: 26445999
N Engl J Med. 1990 Jul 12;323(2):91-6
pubmed: 2359428
Thyroid Res. 2018 Feb 13;11:2
pubmed: 29449887
J Endocrinol Invest. 2020 Sep;43(9):1181-1188
pubmed: 32219692
J Gynecol Obstet Hum Reprod. 2021 Apr;50(4):101815
pubmed: 32562778
Gynecol Endocrinol. 2018 Sep;34(9):752-755
pubmed: 29463152
Endocrinology. 1994 Jun;134(6):2516-23
pubmed: 8194477
Curr Opin Obstet Gynecol. 2016 Jun;28(3):191-7
pubmed: 26967594
J Obstet Gynaecol India. 2017 Apr;67(2):133-136
pubmed: 28405121
Thyroid. 2017 Mar;27(3):315-389
pubmed: 28056690
Contraception. 2003 May;67(5):361-6
pubmed: 12742558
Lancet Diabetes Endocrinol. 2018 Jul;6(7):575-586
pubmed: 29246752
Fertil Steril. 2015 Sep;104(3):545-53
pubmed: 26239023
Eur J Obstet Gynecol Reprod Biol. 2019 Mar;234:207-212
pubmed: 30731333
J Pediatr. 2004 Mar;144(3):394-6
pubmed: 15001954
Geburtshilfe Frauenheilkd. 2014 Nov;74(11):995-1002
pubmed: 25484373
Hum Reprod. 2020 Jun 1;35(6):1306-1318
pubmed: 32478400
Endocrinol Metab (Seoul). 2013 Sep;28(3):221-5
pubmed: 24396682
Hormones (Athens). 2015 Jan-Mar;14(1):59-69
pubmed: 25885104
Ann N Y Acad Sci. 2000;917:809-18
pubmed: 11268410
Biomed Res Int. 2013;2013:503419
pubmed: 24058909
Endocr J. 2000 Dec;47(6):783-5
pubmed: 11228054
Gynecol Endocrinol. 2018 Sep;34(9):734-735
pubmed: 29484896
Front Integr Neurosci. 2013 Aug 13;7:56
pubmed: 23964208
Endocrine. 2016 Apr;52(1):30-8
pubmed: 26475497
Reprod Biol Endocrinol. 2012 Apr 13;10:26
pubmed: 22500852
Nephrol Dial Transplant. 1997 Aug;12(8):1699-700
pubmed: 9269652
Fertil Steril. 2011 Jan;95(1):230-7, 237.e1-2
pubmed: 20691434
J Pediatr Endocrinol Metab. 2010 Apr;23(4):403-6
pubmed: 20583547
Gynecol Endocrinol. 2019;35(sup1):56-59
pubmed: 31532314
Obstet Gynecol. 1985 Nov;66(5):682-90
pubmed: 4058827
Curr Med Sci. 2018 Aug;38(4):626-631
pubmed: 30128871